Speaker：Qiliang Lai（赖其梁）Aoyue Mao（茅傲岳）Jiahui Peng（彭嘉慧）Zhuoran Li（李卓然）

Time：10:00 - 13:00

Abstract:

Human gut microbiome plays an important role throughout our life. It effects on the development and function of the immune system. Immunotherapy has become a promising new method for treating cancer these years. However, this therapy has shown variable efficacy on different patients. Recent studies have linked this difference to gut microbiome. Different people have different gut microbiome composition, and therefore differ in immunotherapy efficacy. These findings provide possible future directions for improving immunotherapy efficacy – by having the “right” bacteria in our gut.

Guest information:

1. Dr. Jian Zhu (PKU)

http://www.bio.pku.edu.cn/teacher_dis_oa.php?cid=146&&teaid=104

2. Dr. Chao Zhong

http://sbms.bjmu.edu.cn/jsdw/bssds/dsjs/186179.htm

Recommend Literatures：

Review:

1. Alexander, James L., et al. "Gut microbiota modulation of chemotherapy efficacy and toxicity." Nature Reviews Gastroenterology & Hepatology 14.6 (2017): 356.

DOI: https://doi.org/10.1038/nrgastro.2017.20

Papers:
1. Viaud, Sophie, et al. "The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide." science 342.6161 (2013): 971-976.

DOI: 10.1126/science.1240537

2. Sivan, Ayelet, et al. "Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy." Science (2015): aac4255.

DOI: 10.1126/science.aac4255